HOME | PRESS RELEASES | HOW TO ORDER | EVALUATE | CONTACT US | CAREERS | Japanese

Benefits of PK Accelerator™

The benefits of deploying PK Accelerator within your drug development enterprise include:

The full suite of Pharsight® software for PK data management, analysis, reporting, and validation

Pharsight's full suite of software creates and unprescedented end-to-end solution built from Pharsight Knowledgebase Server™, Data Import Connectors, WinNonlin® AutoPilot™, PKS Reporter™, WinNonlin & PKS Validation Suites™, Upgrades of WinNonlin Professional to Enterprise, PKS Deployment services following a best practices approach with limited customization, Document templates for validation and PK reporting, Full membership in the Pharsight PKS User Group.

Best practices configuration of all documentation and software settings based on our experience with over 20 pharma and biotech clients

PK Accelerator is based on Pharsight’s best practices experience with over 20 PKS clients in the US, Europe, and Japan.  Key elements of Pharsight’s PK Accelerator solution include: standardized connector settings and transformations, standardized user requirements, standardized validation scripts, standardized PKS and AutoPilot settings, standardized analysis and reporting templates, standardized analysis business rules, and standardized training.

Rapid 3-month deployment reduces uncertainty in your implementation

Having deployed similar solutions in over 20 of the world's largest pharmaceutical and biotech firms, Pharsight's deployment services teams are far down the learning curve in understanding, designing, and executing deployment engagements.  Lessons learned have evolved into best practices and now firms adopting PK Accelerator can benefit from those knowledge assets.

Fixed price of the complete solution eases budgeting and resource planning

Operational Benefits

• Time to produce an NDA report for a project is reduced by as much as 81%

• Easy and fast to refresh a report to fix data errors or included the latest data  

• Many sources of human error are eliminated from the report generation process

• Rapidly build a PK repository, analysis and reporting system that can more easily be brought into compliance with 21CFR Part 11

Strategic Benefits

• Free up scientific staff to focus on critical strategic questions, instead of allocating time to formatting, checking that data is up to date, and performing repetitious calculations - more time can be devoted to strategic thinking, discussion, and review of each project

• More time available for revising study designs

• More use of population PK analysis to optimize trial designs

• More application of PK/PD analysis to pre-clinical projects

• Significantly reduce the workload of valuable QA/QC staff